Synpromics Ltd, a synthetic promoter and gene control company, has entered a collaboration with Sartorius Stedim Cellca to evaluate and test its customized synthetic promoters with Sartorius’ mammalian production cell platform. The program aims to reduce timelines and increase yields in the development of stable cell lines for the production of biopharmaceuticals.
 
Cellca has developed the Cellca CHO Expression Platform, an efficient system for the production of biologicals using CHO (Chinese Hamster Ovary) cells consisting of a cell line, growth medium, expression cassettes and fed-batch process. Cellca has successfully completed more than 40 customer projects using its system. Synpromics has developed a panel of CHO specific synthetic promoters, using its PromPT platform, designed and selected for optimized expression of recombinant proteins.
 
Dr. David Venables, chief executive officer of Synpromics, said, “The majority of recombinant proteins, including monoclonal antibodies, are produced using the CHO system. We believe that the combination of Cellca’s CHO bioprocessing platform with Synpromics’ synthetic promoters will provide a much more efficient production system. We’re aiming for significantly higher levels of product being achieved which will increase capacity while reducing production costs.”
 
Dr. Christoph Zehe, head of Technology Development of Cellca, said, “We are delighted to be working with Synpromics on this exciting project. We believe it will offer significant benefit to our clients in being able to provide a superior production system for biological products.”